一项关于研究药物PF-08634404单药治疗及联合治疗在患有肝癌(肝细胞癌)成年受试者中的研究,该癌症已进展至无法通过手术切除且可能已扩散至身体其他部位。
一项干预性开放标签1B/2期研究,旨在评估PF-08634404作为单药治疗和联合治疗在患有不可切除局部晚期或转移性肝细胞癌的成年参与者中的安全性、药代动力学及初步疗效
The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body.
To join the study, participants must meet the following conditions:
- Be 18 years or older.
- Have locally advanced or metastatic HCC.
- Is not a candidate for complete surgical or loco-regional therapies.
- Have not received any whole-body treatment for HCC.
Participants will receive PF-08634404 either alone or in combination with ipilimumab. The medicine will be given through intravenous (IV) infusions, which means it will be administered directly into a vein. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Pfizer CT.gov Call Center
- 电话号码:1-800-718-1021
- 邮箱:ClinicalTrials.gov_Inquiries@pfizer.com
学习地点
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200032
- 招聘中
- Zhongshan Hospital,Fudan University
-
-
-
-
-
Taichung、台湾、407
- 招聘中
- Taichung Veterans General Hospital
-
Tainan、台湾、704
- 招聘中
- National Cheng Kung University Hospital
-
Taipei、台湾、10002
- 招聘中
- National Taiwan University Hospital
-
Taipei、台湾、112
- 招聘中
- Taipei Veterans General Hospital
-
-
-
-
-
Fukuoka、日本、811-1395
- 招聘中
- National Hospital Organization Kyushu Cancer Center
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、464-8681
- 招聘中
- Aichi Cancer Center
-
-
Chiba
-
Kashiwa、Chiba、日本、277-8577
- 招聘中
- National Cancer Center Hospital East
-
-
Osaka
-
Sakai、Osaka、日本、590-0197
- 招聘中
- Kindai University Hospital- Osaka Medical Campus
-
-
Tokyo
-
Chuo-ku、Tokyo、日本、104-0045
- 招聘中
- National Cancer Center Hospital
-
-
-
-
-
San Juan、波多黎各、00909
- 招聘中
- Pan American Center for Oncology Trials, LLC
-
-
United States of America
-
Dorado、United States of America、波多黎各、00646
- 招聘中
- Pan American Center for Oncology Trials, LLC - Dorado Office
-
Mayagüez、United States of America、波多黎各、00680
- 招聘中
- Pan American Center for Oncology Trials, LLC - Mayaguez Office
-
Ponce、United States of America、波多黎各、00730
- 招聘中
- Pan American Center for Oncology Trials, LLC - Ponce Office
-
-
-
-
California
-
Irvine、California、美国、92612
- 招聘中
- Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Irvine、California、美国、92612
- 招聘中
- UCI Health - Irvine Infusion Pharmacy ACC
-
Irvine、California、美国、92612
- 招聘中
- UCI Health - Irvine
-
Los Angeles、California、美国、90033
- 招聘中
- USC/Norris Comprehensive Cancer Center
-
Los Angeles、California、美国、90033
- 招聘中
- Keck Hospital of USC
-
Los Angeles、California、美国、90033
- 招聘中
- USC/Norris Comprehensive Cancer Center / Investigational Drug Services
-
Los Angeles、California、美国、90033
- 招聘中
- Los Angeles General Medical Center
-
Los Angeles、California、美国、90025
- 招聘中
- START Los Angeles, LLC
-
Los Angeles、California、美国、90067
- 招聘中
- LACN Century City
-
Orange、California、美国、92868
- 招聘中
- UC Irvine Health - Chao Family Comprehensive Cancer Center
-
Pasadena、California、美国、91105
- 招聘中
- Keck Medical Center of USC Pasadena
-
-
Florida
-
Land O' Lakes、Florida、美国、34638
- 招聘中
- Moffitt Cancer Center at Speros
-
Ruskin、Florida、美国、33570
- 招聘中
- Moffitt Cancer Center at SouthShore
-
Tampa、Florida、美国、33612
- 招聘中
- Moffitt Cancer Center - McKinley Campus
-
Tampa、Florida、美国、33612
- 招聘中
- Moffitt Cancer Center
-
Tampa、Florida、美国、33612
- 招聘中
- Moffitt McKinley Hospital
-
Tampa、Florida、美国、33607
- 招聘中
- Moffitt Cancer Center - International Plaza
-
Wesley Chapel、Florida、美国、33544
- 招聘中
- Moffitt Cancer Center at Wesley Chapel
-
-
Illinois
-
Shiloh、Illinois、美国、62269
- 招聘中
- Siteman Cancer Center - Shiloh
-
Shiloh、Illinois、美国、62269
- 招聘中
- Memorial Hospital
-
-
Minnesota
-
Coon Rapids、Minnesota、美国、55433
- 招聘中
- Allina Health Cancer Institute - Mercy Hospital
-
Minneapolis、Minnesota、美国、55407
- 招聘中
- Allina Health Cancer Institute - Abbott Northwestern Hospital
-
Saint Paul、Minnesota、美国、55102
- 招聘中
- Allina Health Cancer Institute - United Hospital
-
-
Missouri
-
City of Saint Peters、Missouri、美国、63376
- 招聘中
- Siteman Cancer Center - St. Peters
-
Creve Coeur、Missouri、美国、63141
- 招聘中
- Siteman Cancer Center - West County
-
Florissant、Missouri、美国、63031
- 招聘中
- Siteman Cancer Center - North County
-
Kansas City、Missouri、美国、64111
- 招聘中
- Saint Luke's Hospital of Kansas City
-
Kansas City、Missouri、美国、64111
- 招聘中
- Saint Luke's Cancer Institute
-
St Louis、Missouri、美国、63108
- 招聘中
- Siteman Cancer Center
-
St Louis、Missouri、美国、63110
- 招聘中
- Washington University School of Medicine - Siteman Cancer Center
-
St Louis、Missouri、美国、63110
- 招聘中
- Barnes-Jewish Hospital
-
St Louis、Missouri、美国、63129
- 招聘中
- Siteman Cancer Center - South County
-
-
Nevada
-
Reno、Nevada、美国、89502
- 招聘中
- Renown Regional Medical Center
-
Reno、Nevada、美国、89502
- 招聘中
- Renown Health Medical Oncology
-
Reno、Nevada、美国、89502
- 招聘中
- Renown Office of Clinical Research
-
-
North Carolina
-
Cary、North Carolina、美国、27518
- 招聘中
- Duke Cancer Center Cary
-
Durham、North Carolina、美国、27710
- 招聘中
- Duke Cancer Center
-
Durham、North Carolina、美国、27710
- 招聘中
- Duke University - Main Hospital and Clinics
-
Durham、North Carolina、美国、27710
- 招聘中
- Duke Cancer Center - Investigational Chemotherapy Service
-
Raleigh、North Carolina、美国、27609
- 招聘中
- Duke Cancer Center Raleigh
-
-
Ohio
-
Cleveland、Ohio、美国、44106
- 招聘中
- University Hospitals Cleveland Medical Center
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15212
- 招聘中
- AHN Allegheny General Hospital
-
Pittsburgh、Pennsylvania、美国、15212
- 招聘中
- AHN Cancer Institute at Allegheny General Hospital
-
-
Washington
-
Seattle、Washington、美国、98101
- 招聘中
- Virginia Mason Medical Center
-
Seattle、Washington、美国、98109
- 招聘中
- Fred Hutchinson Cancer Center
-
Seattle、Washington、美国、98195
- 招聘中
- University of Washington Medical Center- Montlake
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- 18 years of age or older at screening.
- Locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by AASLD criteria (for patients with cirrhosis). Participants without cirrhosis require histological confirmation of diagnosis.
- Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies.
- At least 1 measurable (as defined by RECIST 1.1 per investigator) and untreated lesion.
- Adequate hepatic, liver, and renal function
- No prior systemic therapy for HCC.
- ECOG performance status 0 or 1
- Child-Pugh Class A
Key Exclusion Criteria:
- Moderate or severe ascites.
- History of hepatic encephalopathy.
- Participants with known active CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression.
- Clinically significant risk of hemorrhage or fistula.
- Participants with any history of another malignancy within 3 years.
- History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Participants with active autoimmune diseases requiring systemic treatment within the past 2 years.
- Clinically significant cardiovascular disease within 6 months prior to the first dose.
- Major surgery or severe trauma within 4 weeks prior to the first dose or planned major surgery during the study.
- History of severe bleeding tendency or coagulation dysfunction.
- History of severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding, including bleeding event due to esophageal and/or gastric varices, within 6 months prior to the first dose.
- Participants with acute, chronic or symptomatic infections.
- Participants with history of immunodeficiency.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Phase 1b
Participants will be allocated to sequential dose levels of PF-08634404 and ipilimumab. |
Solution for infusion Solution for infusion
其他名称:
|
|
实验性的:Phase 2
Participants will be randomized to receive either PF-08634404 monotherapy or PF-08634404 combined with ipilimumab. |
Solution for infusion Solution for infusion
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants With Adverse Events
大体时间:Through end of study and up to approximately 24 months
|
Adverse Events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention. |
Through end of study and up to approximately 24 months
|
|
Phase 1b: Number of participants with Dose limiting toxicities (DLT)
大体时间:Through 90 days after the last dose of study intervention; Approximately 24 months
|
DLTs are a predefined set of adverse events that are at least possibly related to any or all of the study interventions. The number of participants who experienced DLTs during the DLT observation period. |
Through 90 days after the last dose of study intervention; Approximately 24 months
|
|
Phase 2: Confirmed Overall Response Rate (ORR) using RECIST 1.1 as assessed by investigator
大体时间:Approximately 24 months
|
ORR is the proportion of participants with a best overall response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 by investigator. |
Approximately 24 months
|
|
Phase 2: Recommended dose of PF-08634404 in combination with ipilimumab
大体时间:Approximately 24 months
|
The doses of PF-08634404 and ipilimumab selected to be used in combination based on safety, tolerability, pharmacokinetics, and initial anti-tumor efficacy from Phase 2. |
Approximately 24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Phase 1b: Confirmed Objective Response Rate (ORR) using RECIST 1.1 as assessed by investigator
大体时间:Approximately 24 months
|
ORR is the proportion of participants with a best overall response of confirmed Complete Response (CR) or confirmed Partial Response (PR) per RECIST 1.1 by investigator. |
Approximately 24 months
|
|
Duration of Response (DOR) per RECIST 1.1 by investigator
大体时间:Approximately 24 months
|
DOR is the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 24 months
|
|
Progression Free Survival (PFS) per RECIST 1.1 by investigator
大体时间:Approximately 24 months
|
PFS is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 24 months
|
|
Overall Survival (OS)
大体时间:Approximately 24 months
|
OS is defined as the time from the date of first dose to the date of death due to any cause. |
Approximately 24 months
|
|
Number of Participants With Clinical Laboratory Abnormalities
大体时间:Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing |
Time from the date of first dose of study intervention through 30-37 days after last dose of study intervention (assessed up to approximately 24 months)
|
|
Pharmacokinetics (PK): Serum concentrations of PF-08634404
大体时间:Up to 24 months
|
Predose and/or postdose concentrations of PF-08634404 in combination with ipilimumab. |
Up to 24 months
|
|
Incidence of antidrug antibody against PF-08634404
大体时间:Up to 24 months
|
To evaluate immunogenicity of PF-08634404 in combination with ipilimumab. |
Up to 24 months
|
合作者和调查者
赞助
调查人员
- 研究主任:Pfizer CT.gov Call Center、Pfizer
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- C6461013
- 2025-523525-17-00 (克蒂斯)
- Symbiotic-GI-13 (其他标识符:Pfizer)
- 2025 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.